

# Juan W Valle

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/3352782/publications.pdf](https://exaly.com/author-pdf/3352782/publications.pdf)

Version: 2024-02-01

253  
papers

30,364  
citations

15360

64  
h-index

5131

164  
g-index

330  
all docs

330  
docs citations

330  
times ranked

25609  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials. <i>Hepatology</i> , 2024, 79, 96-106.	8.1	6
2	Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies. <i>European Journal of Cancer</i> , 2024, 200, 113587.	2.9	3
3	Intrahepatic Cholangiocarcinoma With Extrahepatic Metastasis and High Tumor Mutation Burden: Case of Complete Pathological Response to Cisplatin/Gemcitabine/Pembrolizumab. <i>JCO Precision Oncology</i> , 2024, , .	3.1	0
4	Faecal occult blood loss accurately predicts future detection of colorectal cancer. A prognostic model. <i>Gut</i> , 2023, 72, 101-108.	13.5	10
5	Comparison of biochemical, microbial and mucosal mRNA expression in bile acid diarrhoea and irritable bowel syndrome with diarrhoea. <i>Gut</i> , 2023, 72, 54-65.	13.5	21
6	Relevant Study: Patient and Clinician Perspectives on Clinically-Meaningful Outcomes in Advanced Pancreatic Cancer. <i>Cancers</i> , 2023, 15, 738.	3.8	2
7	Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 462-480.	18.0	15
8	Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma. <i>British Journal of Cancer</i> , 2023, 128, 1672-1680.	6.5	2
9	Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma. <i>Journal of Hepatology</i> , 2023, 79, 93-108.	3.9	57
10	The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study. <i>British Journal of Cancer</i> , 2023, 128, 1922-1932.	6.5	5
11	Prospective Observational Study of Prevalence, Assessment and Treatment of Pancreatic Exocrine Insufficiency in Patients with Inoperable Pancreatic Malignancy (PANcreatic Cancer Dietary) Tj ETQq1 1 0.784314 rgrBT /Overlock 10 T 5		
12	Immunobiology of cholangiocarcinoma. <i>Journal of Hepatology</i> , 2023, 79, 867-875.	3.9	15
13	Third-Line Palliative Systemic Therapy for Advanced Biliary Tract Cancer: Multicentre Review of Patterns of Care and Outcomes. <i>Cancers</i> , 2023, 15, 3047.	3.8	1
14	Patients Undergoing Systemic Anti-Cancer Therapy Who Require Surgical Intervention: What Surgeons Need to Know. <i>Cancers</i> , 2023, 15, 3781.	3.8	1
15	Variation in treatment of intrahepatic cholangiocarcinoma: a nationwide multicentre study. <i>British Journal of Surgery</i> , 2023, 110, 1673-1676.	0.3	2
16	Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma. <i>Current Oncology</i> , 2023, 30, 8665-8685.	2.3	1
17	Locoregional Treatment in Intrahepatic Cholangiocarcinoma: Which Treatment for Which Patient?. <i>Cancers</i> , 2023, 15, 4217.	3.8	2
18	Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy. <i>British Journal of Cancer</i> , 2023, 129, 1766-1772.	6.5	2

#	ARTICLE	IF	CITATIONS
19	Selection of Chemotherapy in Advanced Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma. <i>Cancers</i> , 2023, 15, 4951.	3.8	1
20	Prognosis Discussion and Referral to Community Palliative Care Services in Patients with Advanced Pancreatic Cancer Treated in a Tertiary Cancer Centre. <i>Healthcare (Switzerland)</i> , 2023, 11, 2802.	2.1	1
21	Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 475-485.	2.6	15
22	Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy. <i>British Journal of Cancer</i> , 2022, 126, 693-705.	6.5	23
23	Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 1999-2019.	7.2	22
24	Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). <i>ESMO Open</i> , 2022, 7, 100377.	4.3	13
25	Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes. <i>Oncologist</i> , 2022, 27, 97-103.	4.1	6
26	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. <i>Journal of Hepatology</i> , 2022, 76, 1109-1121.	3.9	153
27	Perspective on Immunotherapy Use in Biliary Tract Cancer. <i>Cancer immunotherapy</i> , 2022, , 207-218.	0.0	0
28	Hepatopancreaticobiliary Cancer in Older Adults with Frailty. , 2022, , 421-445.		0
29	Molecular Profiling of Well-Differentiated Neuroendocrine Tumours: The Role of ctDNA in Real-World Practice. <i>Cancers</i> , 2022, 14, 1017.	3.8	3
30	Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1198-1208.	1.0	3
31	Targeted Therapies for Perihilar Cholangiocarcinoma. <i>Cancers</i> , 2022, 14, 1789.	3.8	7
32	Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 2048-2057.	5.4	84
33	ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective. <i>ESMO Open</i> , 2022, 7, 100392.	4.3	1
34	Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers. <i>ESMO Open</i> , 2022, 7, 100417.	4.3	5
35	Highlights from the 2022 ASCO Gastrointestinal Cancer Symposium: an overview by the EORTC Gastrointestinal Tract Cancer Group. <i>Clinical Colorectal Cancer</i> , 2022, , .	2.4	1
36	Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary. <i>British Journal of Cancer</i> , 2022, 127, 531-540.	6.5	15

#	ARTICLE	IF	CITATIONS
37	Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence. <i>Annals of Surgical Oncology</i> , 2022, 29, 5568-5577.	1.9	5
38	Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. <i>Gut</i> , 2022, , gutjnl-2022-327099.	13.5	14
39	Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. <i>NEJM Evidence</i> , 2022, 1, .	10.0	367
40	Use of the Rockwood Clinical Frailty Scale in patients with advanced hepatopancreaticobiliary malignancies. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1009-1015.	2.5	2
41	The Management and Outcomes of Patients with Extra-Pulmonary Neuroendocrine Neoplasms and Brain Metastases. <i>Current Oncology</i> , 2022, 29, 5110-5125.	2.3	1
42	Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. <i>Hepatology</i> , 2021, 73, 2311-2325.	8.1	45
43	Systemic therapies in advanced hepatocellular carcinoma: How do older patients fare?. <i>European Journal of Surgical Oncology</i> , 2021, 47, 583-590.	1.0	8
44	Outcomes in older patients with biliary tract cancer. <i>European Journal of Surgical Oncology</i> , 2021, 47, 569-575.	1.0	5
45	A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). <i>Oncologist</i> , 2021, 26, e669-e678.	4.1	17
46	Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". <i>British Journal of Cancer</i> , 2021, 124, 679-680.	6.5	0
47	Biliary tract cancer. <i>Lancet, The</i> , 2021, 397, 428-444.	12.1	522
48	Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. <i>European Journal of Cancer</i> , 2021, 144, 200-214.	2.9	13
49	HPB cancers in older patients   inclusion of older/senior patients in clinical trials. <i>European Journal of Surgical Oncology</i> , 2021, 47, 597-602.	1.0	4
50	Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 94, 102168.	8.0	6
51	Ivosidenib: an investigational drug for the treatment of biliary tract cancers. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 301-307.	4.0	5
52	Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT <sup>3</sup> and RADIANT <sup>4</sup> trials. <i>Cancer</i> , 2021, 127, 2674-2682.	4.1	5
53	Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. <i>Lancet Oncology, The</i> , 2021, 22, 690-701.	10.7	446
54	The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours. <i>Frontiers in Endocrinology</i> , 2021, 12, 654975.	3.5	19

#	ARTICLE	IF	CITATIONS
55	Next-Generation Biomarkers for Cholangiocarcinoma. <i>Cancers</i> , 2021, 13, 3222.	3.8	24
56	Erratum to "FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?". <i>ESMO Open</i> , 2021, 6, 100138.	4.3	0
57	Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103328.	4.5	26
58	Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). <i>Journal of Clinical Oncology</i> , 2021, 39, 2304-2312.	5.4	57
59	Second-line FOLFOX chemotherapy for advanced biliary tract cancer " Authors' reply. <i>Lancet Oncology</i> , The, 2021, 22, e288-e289.	10.7	2
60	Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 975-983.	4.0	7
61	Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?. <i>Cancers</i> , 2021, 13, 4152.	3.8	5
62	Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group. <i>British Journal of Cancer</i> , 2021, 125, 911-919.	6.5	3
63	Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2248-2255.	1.0	12
64	Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity. <i>Cancer Cell</i> , 2021, 39, 1227-1244.e20.	16.6	194
65	Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102258.	8.0	58
66	Potential utility of liquid biopsies in the management of patients with biliary tract cancers: A review. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1073-1085.	2.0	6
67	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation. <i>JAMA Oncology</i> , 2021, 7, 1669.	7.3	247
68	Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1468-1482.	10.7	36
69	Chemotherapy for Advanced Pancreatic Cancer: Available Drugs, Mechanisms and Toxicity. , 2021, , 681-696.		0
70	The Potential Role of Liquid Biopsies in Advancing the Understanding of Neuroendocrine Neoplasms. <i>Journal of Clinical Medicine</i> , 2021, 10, 403.	2.5	4
71	Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 101, 102299.	8.0	3
72	Pancreatic Enzyme Replacement Therapy for Patients Diagnosed With Pancreaticobiliary Cancer. <i>Pancreas</i> , 2021, 50, 1254-1259.	1.1	6

#	ARTICLE	IF	CITATIONS
73	hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. <i>Cancers</i> , 2021, 13, 5758.	3.8	5
74	Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis. <i>Nature Communications</i> , 2021, 12, 7336.	13.0	49
75	Current standards and future perspectives in adjuvant treatment for biliary tract cancers. <i>Cancer Treatment Reviews</i> , 2020, 84, 101936.	8.0	79
76	Leukocytosis and alteration of hemoglobin level in patients with severe COVID-19: Association of leukocytosis with mortality. <i>Health Science Reports</i> , 2020, 3, e194.	1.5	13
77	Prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the CLIFF Study. <i>BMJ Open</i> , 2020, 10, e027630.	2.1	6
78	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. <i>British Journal of Cancer</i> , 2020, 123, 1047-1059.	6.5	42
79	FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. <i>Future Oncology</i> , 2020, 16, 2385-2399.	2.4	108
80	Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs). <i>Cancers</i> , 2020, 12, 1988.	3.8	15
81	Fibrolamellar carcinoma: Challenging the challenge. <i>European Journal of Cancer</i> , 2020, 137, 144-147.	2.9	6
82	Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. <i>Cancer Treatment Reviews</i> , 2020, 89, 102084.	8.0	67
83	Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 1682-1688.	1.8	17
84	Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers. <i>Journal of Clinical Medicine</i> , 2020, 9, 2854.	2.5	73
85	Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process. <i>Cancers</i> , 2020, 12, 2375.	3.8	2
86	FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?. <i>ESMO Open</i> , 2020, 5, e000633.	4.3	1
87	The assessment of pancreatic exocrine function in patients with inoperable pancreatic cancer: In need of a new gold-standard. <i>Pancreatology</i> , 2020, 20, 668-675.	1.8	13
88	NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). <i>BMJ Open</i> , 2020, 10, e034527.	2.1	13
89	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClariDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 796-807.	10.7	690
90	NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials. <i>Medical Oncology</i> , 2020, 37, 61.	2.7	11

#	ARTICLE	IF	CITATIONS
91	Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives. <i>Current Opinion in Oncology</i> , 2020, 32, 364-369.	2.5	7
92	Reaching out beyond first-line treatments in advanced biliary tract cancers. <i>Annals of Oncology</i> , 2020, 31, 1099-1102.	1.3	1
93	Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 170-185.	3.9	246
94	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	18.0	1,321
95	The clinical and cost-effectiveness of supplemental parenteral nutrition in oncology. <i>ESMO Open</i> , 2020, 5, e000709.	4.3	12
96	Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. <i>British Journal of Cancer</i> , 2020, 123, 709-713.	6.5	21
97	Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1035-1043.e2.	0.5	52
98	The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2020, 49, 201-207.	1.1	6
99	TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial. <i>British Journal of Cancer</i> , 2020, 122, 971-977.	6.5	34
100	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 398-411.	10.7	161
101	Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1760-1768.	6.5	14
102	Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites. <i>Journal of Hepatology</i> , 2020, 73, 1404-1414.	3.9	72
103	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 1109-1117.	3.9	28
104	Lack of genetic evidence that fatty liver disease predisposes to COVID-19. <i>Journal of Hepatology</i> , 2020, 73, 709-711.	3.9	24
105	Clinical and Translational Research Challenges in Biliary Tract Cancers. <i>Current Medicinal Chemistry</i> , 2020, 27, 4756-4777.	2.4	22
106	NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). <i>Future Oncology</i> , 2020, 16, 1069-1081.	2.4	16
107	Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2571-2580.	5.4	54
108	Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. <i>Scientific Reports</i> , 2019, 9, 11610.	3.4	39



#	ARTICLE	IF	CITATIONS
109	Targeted therapy for cholangiocarcinoma. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 661-662.	8.2	4
110	&lt;p&gt;Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 7537-7556.	2.0	5
111	Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice. <i>Journal of Clinical Medicine</i> , 2019, 8, 1630.	2.5	12
112	Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013&#x2013;2015. <i>British Journal of Cancer</i> , 2019, 121, 966-972.	6.5	50
113	Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2019, 154, 1038.	4.5	179
114	Outcomes in patients&#x2013;years with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy. <i>Medical Oncology</i> , 2019, 36, 85.	2.7	6
115	Sunitinib In Patients With Pancreatic Neuroendocrine Tumors: Update of Safety Data. <i>Future Oncology</i> , 2019, 15, 1219-1230.	2.4	17
116	Recruitment and Trial-Finding Apps&#x201c;Time for Rules of the Road. <i>Journal of the National Cancer Institute</i> , 2019, 111, 882-886.	6.3	3
117	&lt;p&gt;Biliary tract cancers: current knowledge, clinical candidates and future challenges&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 2623-2642.	2.0	85
118	Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 663-673.	10.7	839
119	Medical treatment for cholangiocarcinoma. <i>Liver International</i> , 2019, 39, 123-142.	3.9	72
120	Adjuvant chemotherapy and outcomes in patients with nodal and resection margin&#x2013;negative pancreatic ductal adenocarcinoma: A systematic review and meta&#x2013;analysis. <i>Journal of Surgical Oncology</i> , 2019, 119, 932-940.	1.7	11
121	Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 1015-1027.	5.4	325
122	18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2019, 71, 115-129.	3.9	86
123	Novel Treatments for Advanced Cholangiocarcinoma. , 2019, , 227-243.		1
124	Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. <i>Pancreatology</i> , 2019, 19, 97-104.	1.8	35
125	Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC). <i>Clinical and Translational Oncology</i> , 2019, 21, 950-953.	2.5	10
126	The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2019, 269, 520-529.	4.4	199



#	ARTICLE	IF	CITATIONS
127	Evaluation and management of incidental gallbladder cancer. <i>Chinese Clinical Oncology</i> , 2019, 8, 37-37.	1.3	15
128	Systemic therapy of gallbladder cancer: review of first line, maintenance, neoadjuvant and second line therapy specific to gallbladder cancer. <i>Chinese Clinical Oncology</i> , 2019, 8, 43-43.	1.3	17
129	Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. <i>British Journal of Cancer</i> , 2018, 118, 947-954.	6.5	30
130	Intratumoural expression of deoxycytidylate deaminase or ribonucleotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. <i>British Journal of Cancer</i> , 2018, 118, 1084-1088.	6.5	10
131	A study of appendiceal crypt cell adenocarcinoma (so-called goblet cell carcinoid and its related) Tj ETQq1 1 0.784314 rgBT /Overlock 2.3 25	2.3	25
132	Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response. <i>British Journal of Cancer</i> , 2018, 118, 181-188.	6.5	23
133	Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer. <i>Nature Communications</i> , 2018, 9, 4672.	13.0	49
134	Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma—a meta-analysis. <i>European Journal of Cancer</i> , 2018, 105, 1-9.	2.9	73
135	The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers. <i>PLoS ONE</i> , 2018, 13, e0206007.	2.5	15
136	Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 947-958.	1.6	5
137	Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair. <i>Cancer Treatment Reviews</i> , 2018, 70, 168-177.	8.0	59
138	Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. <i>Clinical Therapeutics</i> , 2018, 40, 952-962.e2.	2.3	20
139	Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. <i>British Journal of Cancer</i> , 2018, 119, 27-35.	6.5	19
140	Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. <i>Cancers</i> , 2018, 10, 17.	3.8	26
141	Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment?. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1486-1493.	1.0	11
142	Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 723-731.	3.0	41
143	PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. <i>Oncotarget</i> , 2018, 9, 14922-14938.	1.9	32
144	Elderly patients diagnosed with hepatopancreatobiliary malignancies: A challenge beyond resection. <i>Cancer</i> , 2017, 123, 888-890.	4.1	2

#	ARTICLE	IF	CITATIONS
145	Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet</i> , The, 2017, 389, 1011-1024.	12.1	1,542
146	Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 486-499.	10.7	62
147	Effectiveness of Progressive Resistive Exercise (PRE) in the context of HIV: systematic review and meta-analysis using the Cochrane Collaboration protocol. <i>BMC Infectious Diseases</i> , 2017, 17, 268.	3.0	92
148	The dark side of T1 non-appendiceal small bowel neuroendocrine tumors. <i>Human Pathology</i> , 2017, 66, 239-240.	2.3	0
149	A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. <i>Annals of Oncology</i> , 2017, 28, 1309-1315.	1.3	84
150	HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 141-157.	6.2	131
151	Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1411-1422.	10.7	76
152	New molecular and immunotherapeutic approaches in biliary cancer. <i>ESMO Open</i> , 2017, 2, e000152.	4.3	28
153	Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw277.	6.3	33
154	New Horizons for Precision Medicine in Biliary Tract Cancers. <i>Cancer Discovery</i> , 2017, 7, 943-962.	14.1	438
155	A protocol for a cluster-randomized controlled trial of a self-help psycho-education programme to reduce diagnosis delay in women with breast cancer symptoms in Indonesia. <i>BMC Cancer</i> , 2017, 17, 284.	2.6	5
156	Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma. <i>Current Oncology Reports</i> , 2017, 19, 50.	4.1	18
157	The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1425-1436.	4.4	290
158	Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. <i>Annals of Oncology</i> , 2017, 28, 339-343.	1.3	151
159	Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours. <i>Clinical and Translational Oncology</i> , 2017, 19, 579-586.	2.5	33
160	Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 909.	4.2	22
161	Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5013-5030.	2.1	8
162	Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. <i>Journal of Clinical Oncology</i> , 2017, 35, 14-23.	5.4	269

#	ARTICLE	IF	CITATIONS
163	Circulating Tumour Cells. , 2017, , 1-36.		0
164	Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. Journal of Gastrointestinal Oncology, 2016, 7, 819-827.	1.4	17
165	Pancreatic cancer: Are "liquid biopsies" ready for prime-time?. World Journal of Gastroenterology, 2016, 22, 7175.	3.4	25
166	Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial. Targeted Oncology, 2016, 11, 815-824.	3.7	45
167	Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery. Surgical Oncology, 2016, 25, 223-228.	1.8	13
168	Quality of life, long-term survivors and long-term outcome from the ABC-02 study. British Journal of Cancer, 2016, 114, 965-971.	6.5	41
169	Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder. British Journal of Cancer, 2016, 115, 1032-1038.	6.5	26
170	Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. British Journal of Cancer, 2016, 115, 420-424.	6.5	10
171	Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2016, 27, v28-v37.	1.3	545
172	Everolimus in the Treatment of Neuroendocrine Tumors of the Respiratory and Gastroenteropancreatic Systems. Future Oncology, 2016, 12, 2561-2578.	2.4	3
173	Telotristat ethyl: a new option for the management of carcinoid syndrome. Expert Opinion on Pharmacotherapy, 2016, 17, 2487-2498.	1.9	29
174	Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement. Annals of Clinical Biochemistry, 2016, 53, 554-560.	1.6	64
175	A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer, 2016, 16, 153.	2.6	64
176	Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?. Cancer Treatment Reviews, 2016, 44, 26-41.	8.0	46
177	Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study. Digestive and Liver Disease, 2016, 48, 552-558.	0.9	45
178	Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet, The, 2016, 387, 968-977.	12.1	1,002
179	<sup>18</sup> F-FLT PET imaging of cellular proliferation in pancreatic cancer. Critical Reviews in Oncology/Hematology, 2016, 99, 158-169.	4.5	11
180	Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Annals of Oncology, 2016, 27, 134-140.	1.3	88

#	ARTICLE	IF	CITATIONS
181	Prevalence of symptomatic pancreatic exocrine insufficiency in patients with pancreatic malignancy: nutritional intervention may improve survival. <i>Cancer Research Frontiers</i> , 2016, 2, 352-367.	0.2	10
182	Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy. <i>World Journal of Gastroenterology</i> , 2016, 22, 6065.	3.4	24
183	A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs. <i>Journal of Gastrointestinal Cancer</i> , 2015, 46, 201-211.	1.4	205
184	Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 115-122.e2.	2.4	43
185	Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer. <i>European Journal of Cancer</i> , 2015, 51, 1381-1388.	2.9	20
186	Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease. <i>European Journal of Cancer</i> , 2015, 51, 1694-1703.	2.9	25
187	Characterization and Expression of Outer Membrane Protein A I Gene of <i>Aeromonas veronii</i> . <i>The Journal of Northeast Agricultural University</i> , 2015, 22, 15-21.	0.1	3
188	Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 967-978.	10.7	228
189	Cetuximab Is Contraindicated in the Perioperative Treatment of Colorectal Liver Metastases. <i>Journal of Clinical Oncology</i> , 2015, 33, 2405-2406.	5.4	7
190	Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 1099-1114.	2.4	13
191	The role of adjuvant chemotherapy and radiotherapy for cholangiocarcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 333-343.	2.4	32
192	Telotristat Etiprate for Carcinoid Syndrome: A Single-Arm, Multicenter Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1511-1519.	3.6	99
193	Variation in Cardiac Screening and Management of Carcinoid Heart Disease in the UK and Republic of Ireland. <i>Clinical Oncology</i> , 2015, 27, 741-746.	1.4	18
194	Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality. <i>British Journal of Cancer</i> , 2014, 111, 1703-1709.	6.5	42
195	Second-line chemotherapy in advanced biliary cancer: a systematic review. <i>Annals of Oncology</i> , 2014, 25, 2328-2338.	1.3	287
196	Reply to the letter to the editor "Second-line chemotherapy in advanced biliary cancer: the present now will later be past" by Vivaldi et al.. <i>Annals of Oncology</i> , 2014, 25, 2444-2445.	1.3	1
197	Combination therapy of <sup>177</sup> Lu and <sup>90</sup> Y Dotatate for treatment of neuroendocrine cancer. <i>Nuclear Medicine Communications</i> , 2014, 35, 585-587.	1.1	0
198	Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. <i>Cancer Treatment Reviews</i> , 2014, 40, 1230-1238.	8.0	34

#	ARTICLE	IF	CITATIONS
199	Evaluation of Hypertension and Proteinuria as Markers of Efficacy in Antiangiogenic Therapy for Metastatic Colorectal Cancer. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 430-434.	2.3	26
200	Capecitabine and streptozocin±cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. <i>European Journal of Cancer</i> , 2014, 50, 902-911.	2.9	57
201	Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study. <i>Translational Oncology</i> , 2014, 7, 55-64.	3.8	16
202	A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours. <i>Cancer Treatment Reviews</i> , 2014, 40, 376-389.	8.0	46
203	Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt347.	6.3	237
204	The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 175-183.	4.4	81
205	A comparison of diagnostic imaging modalities for colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , 2014, 40, 545-550.	1.0	35
206	Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 504-512.	5.4	364
207	Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 829-840.	10.7	306
208	Erratum to "A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours" [Cancer Treat Rev 40 (2014) 376-389]. <i>Cancer Treatment Reviews</i> , 2014, 40, 1037.	8.0	3
209	Circulating biomarkers in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 323-332.	2.4	58
210	Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. <i>Annals of Oncology</i> , 2014, 25, 391-398.	1.3	329
211	Methods for Adjusting for Bias Due to Crossover in Oncology Trials. <i>Pharmacoeconomics</i> , 2014, 32, 533-546.	3.6	43
212	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 601-611.	10.7	376
213	BINGO: targeted therapy for advanced biliary-tract cancer. <i>Lancet Oncology</i> , The, 2014, 15, 778-780.	10.7	5
214	Looking Beyond Chemotherapy in Patients with Advanced, Well-differentiated, Pancreatic Neuroendocrine Tumors. <i>The Journal of Oncopathology</i> , 2014, 2, 15-25.	0.1	2
215	Should Patients with Resected Bile Duct Cancer Receive an Adjuvant Treatment?. <i>The Journal of Oncopathology</i> , 2014, 2, 57-68.	0.1	3
216	Clinical Management of Targeted Therapies in Neuroendocrine Tumours. , 2014, , 141-154.		0

#	ARTICLE	IF	CITATIONS
217	Outcome of second-line chemotherapy for biliary tract cancer. <i>European Journal of Cancer</i> , 2013, 49, 1511.	2.9	45
218	The Association of a Panel of Biomarkers with the Presence and Severity of Carcinoid Heart Disease: A Cross-Sectional Study. <i>PLoS ONE</i> , 2013, 8, e73679.	2.5	53
219	A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. <i>British Journal of Cancer</i> , 2012, 106, 508-516.	6.5	236
220	Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periapillary Adenocarcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 147.	7.0	516
221	Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. <i>New England Journal of Medicine</i> , 2011, 364, 501-513.	29.7	2,255
222	Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 31-39.	4.5	34
223	Sunitinib for advanced pancreatic neuroendocrine tumors. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1817-1827.	2.5	7
224	A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. <i>Investigational New Drugs</i> , 2011, 29, 1029-1037.	2.7	272
225	Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 2004-2010.	5.4	151
226	Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. <i>British Journal of Cancer</i> , 2010, 103, 315-323.	6.5	9
227	Reply: Guesstimates are not good enough for determining what is happening in routine care. <i>British Journal of Cancer</i> , 2010, 103, 1887-1888.	6.5	0
228	Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1073.	7.0	1,225
229	Advances in the treatment of metastatic or unresectable biliary tract cancer. <i>Annals of Oncology</i> , 2010, 21, vii345-vii348.	1.3	77
230	A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer. <i>European Journal of Cancer</i> , 2010, 46, 526-533.	2.9	30
231	Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. <i>New England Journal of Medicine</i> , 2010, 362, 1273-1281.	29.7	3,522
232	Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5513-5518.	5.4	715
233	Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study "The UK ABC-01 Study". <i>British Journal of Cancer</i> , 2009, 101, 621-627.	6.5	245
234	<i>UGT1A1*28</i> Genotype Predicts Gastrointestinal Toxicity in Patients Treated With Intermediate-Dose Irinotecan. <i>Pharmacogenomics</i> , 2009, 10, 733-739.	1.4	34



#	ARTICLE	IF	CITATIONS
235	Pneumoperitoneum Following Percutaneous Biliary Intervention: Not Necessarily a Cause for Alarm. CardioVascular and Interventional Radiology, 2008, 31, 439-443.	2.1	3
236	A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology, 2008, 61, 579-585.	2.4	17
237	Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer. British Journal of Cancer, 2008, 99, 577-583.	6.5	7
238	Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a Phase I study. British Journal of Cancer, 2007, 96, 38-43.	6.5	12
239	Patients With Pancreatic Cancer Participating in Clinical Trials. Pancreas, 2007, 34, 269-270.	1.1	1
240	A Phase II Study of Weekly Cisplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer: Is This a Strategy Still Worth Pursuing?. Pancreas, 2006, 32, 51-57.	1.1	12
241	Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. British Journal of Cancer, 2006, 95, 450-456.	6.5	10
242	Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor. Journal of Cancer Research and Clinical Oncology, 2006, 132, 41-44.	2.6	9
243	Irinotecan with Bolus and Infusional 5-fluorouracil and Folinic Acid for Patients with Advanced or Metastatic Colorectal Cancer Previously Treated with 5-fluorouracil: A Possible Alternative to Single-agent Irinotecan in a "Real-life"™ Setting. Clinical Oncology, 2005, 17, 666.	1.4	0
244	Blockade of Platelet-Derived Growth Factor Receptor-Beta by CDP860, a Humanized, PEGylated di-Fab', Leads to Fluid Accumulation and Is Associated With Increased Tumor Vascularized Volume. Journal of Clinical Oncology, 2005, 23, 973-981.	5.4	168
245	Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study. British Journal of Cancer, 2005, 92, 628-630.	6.5	24
246	Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer. British Journal of Cancer, 2004, 91, 1447-1452.	6.5	4
247	Reply 1: Call for NICE to review urgently their guidance concerning first-line chemotherapy for metastatic colorectal cancer. British Journal of Cancer, 2003, 88, 1153-1154.	6.5	0
248	Why hasn't the National Institute been "NICE"™ to patients with colorectal cancer?. British Journal of Cancer, 2002, 86, 1667-1669.	6.5	8
249	Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma. Cancer, 2001, 92, 601-608.	4.1	49
250	Adjuvant therapy for gastric cancer " has the standard changed?. British Journal of Cancer, 2001, 84, 875-877.	6.5	4
251	Pharmacokinetics of a hematoregulatory peptide (SK&F107647) in healthy male volunteers and in patients with colorectal or pancreatic adenocarcinoma not amenable to standard therapy. Pharmaceutical Research, 2000, 17, 385-390.	3.5	2
252	i and fatal neutropen and fatal neutropenic enterocolitis following adjuvant chemotherapy for breast cancer. Clinical Oncology, 1997, 9, 172-175.	1.4	6



#	ARTICLE	IF	CITATIONS
253	Carboplatin-etoposide chemotherapy for patients with advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC); outcomes from a European Neuroendocrine Tumour Society Centre of Excellence. Endocrine Abstracts, 0, , .	0.0	1